Brought to you by 
Quidel acquires BioHelix for $10mm plus undisclosed earn-outs
11 Sep 2020
Executive Summary
Diagnostics firm Quidel Corp. has acquired closely held BioHelix Corp. (isothermal molecular assays) for $10mm up front plus two separate undisclosed earn-outs, one linked to completion of R&D on assays and the other tied to product sales over a certain time period. BioHelix will become a wholly owned subsidiary and retains its president Huimin Kong, PhD.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Quidel acquires BioHelix for $10mm plus undisclosed earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice